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ABSTRACT
Several evidences have shown that BRCA mutations increased tumor-cells 
sensitivity to PARP inhibitors by synthetic lethality leading to an accelerated 
development of several compounds targeting the PARP enzymes system as anticancer 
agents for clinical setting. Most of such compounds have been investigated in 
ovarian and breast cancer, showing promising efficacy in BRCA-mutated patients. 
Recently clinical studies of PARP-inhibitors have been extended across different 
tumor types harboring BRCA-mutations, including also “BRCA-like” sporadic tumors 
with homologous recombination deficiency (HRD). This review summarizes the 
biological background underlying PARP-inhibition, reporting the results of the most 
relevant clinical trials carried out in patients treated with PARP inhibitors alone 
or in combination with chemotherapy. Molecular mechanisms responsible for the 
occurrence of both primary and acquired resistance have been elucidated, in order 
to support the development of new treatment strategies.
INTRODUCTION
The personalized therapeutic strategy targeting 
specific molecular alterations involved into tumorigenesis 
is the new frontier of cancer treatment. Dysfunction of 
DNA damage repair from cancer, impairing the integrity 
of the genome, could be a valuable target for anticancer 
therapy.
BRCA germline mutations represent the molecular 
basis for the majority of hereditary breast and ovarian 
cancer (HBOC) syndrome. BRCA1 and BRCA2 are tumor 
suppressor genes encoding proteins essential for DNA 
repair, involved in key processes for the maintenance of 
genomic stability [1].
Specifically BRCA1/2 are essential for the accurate 
repair of DNA double-strand breaks (DSBs) through 
homologous recombination (HR) [2]. This mechanism of 
DNA repair is conservative and it allows to restore the 
original sequence of the DNA [3].
Mutations in BRCA1 or BRCA2 result in protein 
isoforms unable to repair DSBs by HR. The HR-deficient 
cells use alternative DNA-damage response (DDR) 
pathway. This compensatory repair mechanism is non-
conservative, causes genomic instability and make the 
tumor cells subordinated to their proper functioning to 
survival [2, 3].
Germline mutations in tumor suppressors BRCA1/2 
result in an increased risk of developing breast, ovarian 
and others, such as pancreas, stomach and prostate cancers 
[4, 5]: the neoplastic process will rise if the wild-type gene 
is lost or inactivated.
Other genes and low penetrance alleles can be 
involved in HBOC susceptibility including some genes 
encoding for proteins involved in HR DNA repair 
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pathway, such as RAD50, RAD51C, RAD51D, PALB2, 
CHEK2, MRE11A, BARD1, BRIP 1, NBS1 and ATM 
[3]. Furthermore alterations in such genes have been 
identified also in sporadic breast tumors with early age 
of onset, hormone receptors (ER/PgR) negativity and a 
high tumor grade, but in absence of germline BRCA1/2 
mutations, which define a BRCA-like phenotype defined 
as “BRCAness” [5].
All these findings suggest that DNA repair process 
and specially the HR are associated with the onset of many 
tumors and have today important therapeutic implications 
for patients: the loss of a functional copy of BRCA1/2 is 
a workable target for using a synthetic lethal approach to 
treat BRCA-deficient cancers [6].
The concept of synthetic lethality between two 
genes imply that the concomitant damage of both produces 
the cell death. Conversely, the loss of either gene allows 
cell survival. BRCA1/2 and Poly(ADPribose) polymerase 
1 (PARP1) genes are a model of synthetic lethality [7]. 
PARP1 encodes an enzyme with an important role in DNA 
single-strand break repair (SSBs) [8].
PARP inhibitors (PARPi), an emerging class of 
drugs, are synthetically lethal against BRCA1/2-deficient 
cancer cells. In these cells the PARP inhibition produces 
accumulation of genetic aberrations that cannot be 
restored through BRCA1/2-homologous recombination 
[9]. The PARPi target is, therefore, the dysregulation of 
DNA repair pathway and the subsequent addiction of the 
BRCA-mutated tumors by the function of compensatory 
repair mechanism.
PARPi have been developed and tested in clinical 
trials to treat patients carrying BRCA1/2 mutations. These 
genetic alterations have been detected in about 17% of 
patients with ovarian cancer, mainly high grade serous 
adenocarcinoma. These findings prompted the approval of 
the first PARPi olaparib in Dicember 2014 as monotherapy 
for the treatment of patients with advanced ovarian cancer 
and BRCA1/2 germline mutations who have received 
three or more prior lines of chemotherapy [10-12].
Currently, several clinical trials are investigating 
the effectiveness of new PARPi, alone or in combination 
with chemotherapy or targeted therapy [13]. Moreover, the 
discovery of somatic BRCA mutations also in other cancer 
provides new and promising applications for PARPi.
Most data from clinical trials suggests that some 
patients initially treated with PARPi eventually develop 
resistance [14]. The mechanisms of resistance are multiple 
and they typically restore the function of DDR pathway 
[15, 16].
BIOLOGY OF PARP INHIBITION
Several genotoxic agents, including reactive 
oxygen species, ultraviolet light, ionizing radiation, and 
endogenous and synthetic compounds may lead to single 
strand break (SSB) or double strands breaks (DSB) at the 
DNA helix, which are physiologically repaired by different 
systems that provide the restoration and maintenance of 
DNA integrity [17]. 
During replication (cell cycle S phase) polymerases 
usually replace the incorrect single nucleotides insertions 
by proofreading and exonuclease activity, whereas if the 
new synthesized strand presents deletions, insertions or 
wrong bases incorporations, mismatch repair mechanisms 
(MMR) will be activated. 
Both polymerases and MMR are able to repair only 
“simple” replication errors consisting of single nucleotides 
alterations. If more “complex alterations” occur, such as 
chromosomal rearrangements and transposons, the final 
effect will be the DNA damage.
In this case the cells put in place two main strategies 
aiming to correct these negative events: first stopping the 
cell cycle, and subsequently activating the repair cellular 
pathways. If the damage cannot be corrected cells will die 
by apoptosis. After the detection of DNA lesions several 
check-point proteins are recruited, including DNA-
dependent protein kinase (DNA-PK), ataxia-telangiectasia 
mutated (ATM) and and Rad3-related kinase (ATR). All 
these are serine threonine-kinase enzymes responsible for 
the activation of specific damage-related repair systems 
during the check-point response. The activation of repair 
mechanisms is correlated to the specific DNA damage 
causes and extent.
The two main cellular systems responsible for the 
correction of the SSB are called: Base Excision Repair 
(BER) and Nucleotide Excision Repair (NER).
BER occurs after X rays, oxygen radicals, alkylating 
agents or spontaneous reactions which alter the nucleotide 
bases during S and G2 phases; while NER complex is 
activated by UV light, which arises pyridine dimers or 
large DNA adducts, and has an important role during G1 
phase [18, 19]. 
BER system activity is initiated by a DNA 
glycosylase which recognizes the damaged site and 
removes the nucleotide base; after that, X-ray repair 
cross-complementing gene 1 (XRCC1) protein, DNA 
polymerase B (polβ), exo and endo-nucleases enzymes are 
recruited and provide to the repair, synthesis and ligation 
of DNA [20, 21]. Another enzyme involved in the BER 
pathway, is the poly ADP-ribose polymerases (PARP). 
PARP is a post-translation protein that synthesizes 
ADP-ribose polymers (PAR) on target proteins by the 
nicotinamide adenine dinucleotide NAD+ substrate, 
facilitating the annealing of system repairs. These enzymes 
have a pleiotropic function in response to genotoxic 
stressors aiming to maintain the genomic stability. They 
take part to different processes: cellular metabolism and 
death, chromatin modification, insulator function, mitotic 
apparatus response, and transcriptional regulation. PARP1 
was the first member of the members of PARP’s family 
proteins identified. PARP 1 is a multi-domain protein: the 
amino-terminal DNA-binding domain (DBD) contains 
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zinc finger domains and a bipartite nuclear localization 
signal (NLS); the auto-modification domain (AD), and 
the carboxyl-terminal PARP homology domain, which 
includes the catalytic domain (CAT) responsible for PAR 
formation. The damage in DNA is recognized by PARP1 
through zinc fingers FI and FII domains. PARP1 early 
recognizes nicked DNA and organizes the recruitment of 
the different repair systems, accumulating PAR protein 
Figure 1: PARP inhibitor acquired resistance mechanism. Based from pre-clinical studies, several alteration are responsible of 
partial or complete restoration of the HR repair function: secondary mutations in BRCA1-2; loss of 53BP1 protein function; Pgp over-
expression and PARPi efflux.
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targets. PARP1 is itself the major acceptor of PAR, used to 
attract and assist the assembling multi-protein complexes 
in chromatin remodeling, DNA repair and damage 
checkpoint signaling [22, 23]. DNA repair scaffolds 
as XRCC1 may be directly recruited by auto-modified 
PARP1. PARP1 also recruits the DNA check-point protein 
ATM activating the signaling cascade for DNA damage 
and cell cycle arrest. 
NER system acts by several enzymes, including 
XPA, RPA, XPG, TFIIH. Among them there are 
endonucleases, DNA helicases, DNA synthesis and 
ligation enzymes. NER system can be divided into global 
repair and transcription-coupled repair (TCR). The last 
one specifically aims to repair lesions of transcribed genes.
Similarly there are two main pathways regulating 
DSB repair: homologous recombination repair (HRR), 
and non-homologous end-joining (NHEJ). NHEJ may be 
activated during G1-phase acting without an homologous 
template to guide repair process. Therefore it’s defined as 
an “error-prone” system which often causes the occurrence 
of further mutations. 
NHEJ includes a multistep reaction starting with 
both Ku 70 and Ku 80 binding proteins which rapidly 
constitutes a complex with DNA-dependent kinase and 
ligase proteins, in order to repair the breaks at DNA ends.
Recent studies have shown a determinant role of 
NHJE systems in the repair to DNA damage caused by 
radiomimetic drugs, ionizing radiation (IR), or ultraviolet 
(UV) light, suggesting that the recruitment of an “error-
prone” system, like NHJE, may increase the cells’ genetic 
instability [24]. 
HRR is the most accurate mechanism among 
the DSBs during S - G2 phases because the source of 
information is represented by the sister chromatids 
which are used like a template to repair the damaged 
DNA. HRR is introduced mainly by the so-called MNR 
complex, including MRE11, RAD50, and NBS1 proteins, 
which regulates the generation of single strand ends of 
DNA (ssDNA), at DSB site, thus mediating the ATR 
recruitment. Furthermore MNR-complex interacts with 
ATM, playing a crucial role for the beginning of HRR 
cascade, by the activation of CHEK1, CHEK2, P53, 
NSB1, and BRCA proteins and downstream signaling 
pathways [25]. The HRR mechanism begins with 5′ to 
3′ end-processing at broken ends of the DNA fragments 
which need to be repaired. The 3’ end of ssDNA, arised 
by exonuclease, are stabilized, through the intervention of 
RAD (RAD 51, RAD52) and RAP proteins. BRCA2 then 
mediates the substitution of RAP1 with RAD51, and leads 
the pre-synaptic filament towards the homologous DNA 
template. Following the complementary strands pairing 
the DNA polymerase can extend the DNA strand, finally 
leading to the repaired heteroduplexed DNA which is 
characterized by the formation of the “Holliday junctions”.
HRR defective seems to be a major contributor 
to tumorigenesis in individuals carrying ATM, CHEK2, 
RAD51, MNR, and germline and somatic mutations 
of BRCA, defining a tumor cells phenotype known as 
homologous recombination deficiency (HRD). 
The crucial role of the breast cancer susceptibility 
proteins, BRCA1 and BRCA2 in the DNA repair has been 
known since 1995 [26]. These proteins are considered 
the product of two distinct tumor suppressor genes which 
play a crucial role in the response to cellular stressors and 
in the activation of DNA repair processes. BRCA1 and 
BRCA2 germline mutations predispose to develop breast 
and ovarian cancer and also increases the risk to develop 
other cancer types including pancreatic cancer, prostate 
cancer, and melanoma [27-29].
In details, BRCA1 protein provides to: G1-S and 
G2-M transition checkpoints, transcriptional regulation and 
chromatin remodeling. BRCA1 is rapidly phosphorylated 
after DNA damage in dividing cells by different kinases. 
The different roles of BRCA1 is guaranteed by its 
several domains that allow to regulate various processes 
by specific interactions with other cellular factors. 
Among them are included: nuclear localization signals 
NLS, binding sites for proteins p53, cMyc, RB and a 
transcriptional repressor ZBRK1. These proteins are 
known as “guardian of genome” for their crucial role in 
cancer development prevention and cell cycle progression 
restoration. Another site is the binding domain to recruit 
the chromatin remodeling SW1-SNF system, which is 
able to create a free access to other factors involved in 
the repair mechanisms. BRCA1 fulfills its transcriptional 
regulation role interacting by BRCA C - Terminal binding 
site (BRCT), with RNA polymerase II, the complex p300-
CBP transcriptional co-activating proteins, transcription 
regulator protein BACH1, the histone complexes - 
deacetylase HDAC1 and HDAC2. These activated 
complexes are needed to maintain chromatins relaxed 
and to promote gene expression through the recruitment 
of the basal transcriptional machinery. BRCT also favors 
the binding between BRCA and CtIP, an enzyme which 
together with MRN complex allows the beginning of HRR 
pathway. Recent studies suggested that a large group of 
cellular proteins interact with BRCA1 favoring the 
activity of HRR as the predominant mechanism to ensure 
the genomic stability. In contrast, HRR is not efficient 
in BRCA1 deficient cells, and the chromatin breaks are 
often rejoined by components of NHEJ in aberrant fusion 
between heterologous chromosomes [30].
As regards BRCA2 protein it seems to act directly in 
HRR, by interacting with RAD 51 protein into the nucleus. 
The interactions between BRCA2 and RAD 51 seem to 
be negatively regulated by cycline A-CDK2, and a recent 
study has shown that cycline D1-CDK4 destablished the 
cycline A-CDK2 complex, promoting BRCA2-RAD51 
activity, and ultimately improving the HHR.
BRCA2 seems to interact also with the Fanconi’s 
anemia protein ubiquitylation pathway, contributing to 
regulate protein-protein interactions and/or accessibility 
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of repair factors to the damage sites. When FA genes are 
deficient the BRCA-mediated HHR doesn’t work correctly 
and NHEJ will be recruited determining an increase of the 
genomic instability [31, 32]. 
A deeper understanding of the molecular pathways 
underlying the DNA repair mechanisms have led to the 
advent of a new family of targeted drugs able to inhibit 
PARPs proteins. The clinical development of these drugs 
was based on several evidences provided by preclinical 
studies, which attested the possibility to induce cancer 
cells die by “synthetic lethality”. This model consists of 
determining the simultaneous block of two main DNA 
repair pathways in the same cancer cell, ultimately 
inducing cell death by apoptosis. The first study in 
xenograft models has shown that once inactivated by 
inhibitors, PARP1 lost the ability to interact with the single 
strand repair system preventing DNA repair via the BER 
pathway. The accumulation of SSB leads to the collaps 
of the replication forks translating into DSB, which if 
not immediately repaired by HRR system, results into 
the cell death. This is precisely what happened in cancer 
cells defective for HRR pathways, as a result of BRCA1/2 
mutations [33-35]. Indeed, in absence of a functional HRR 
system, these lesions are usually repaired by alternative 
error-prone pathways, such as NHEJ and single strand 
annealing (SSA) resulting in gross genomic instability and 
ultimately leading to the cell death. 
However all the potential interactions between 
PARP1 and HRR pathway, have not been well-elucidated 
[36]. Experimental data suggest that PARP inhibition 
increases spontaneous HRR , but it had no effects on DSB-
induced HRR [37]. Other studies have shown a possible 
relationship between PARP enzymes and BRCA proteins, 
likely involving BRCA2. Indeed BRCA2 contains three 
tandem oligonucleotide oligosaccharide binding folds 
(OB-folds ) involved in DNA binding during DNA DBS 
repair. This domain recognizes PAR and mediates the fast 
recruitment of BRCA2 to the DNA lesion needed for the 
first steps of HRR [38].
Subsequently several both pre-clinical and clinical 
studies confirmed that the sensitivity to PARPi is not 
limited to cells harboring BRCA 1/2 mutations, but 
occurs also in cells carrying mutated genes encoding other 
proteins involved in HRR system. The hypermethylation 
of the BRCA1 promoter or the loss of function of other 
genes as ATM, CHEK2, RAD51, BRIP1, and PALB2 
belonging at DNA repair machinery, define a specific 
phenotype with features and behavior similar to BRCA-
related cancers, defined as “BRCAness”. These patients 
might benefit from platinum-based therapies and/or PARP 
inhibition like BRCA mutated [39-42].
CLINICAL DEVELOPMENT OF PARP 
INHIBITORS
To date there are about ten molecules, including 
olaparib, veliparib, rucaparib, niraparib, among those 
in more advanced stages of experimental development. 
The majority of such studies have been focused on solid 
tumors harboring germ-line BRCA1-2 mutations, mainly 
ovarian and breast, but also prostate or pancreatic cancers. 
However the use of PARP inhibitors as single agent was 
extended also to “BRCA-like” sporadic tumors with 
suspected homologous recombination (HR) genes defects, 
including high grade serous ovarian cancer (HGSOC) and 
triple negative breast cancer (TNBC). Furthermore the 
peculiar mechanisms of action of such compounds has 
led to evaluate potential combinations with both DNA 
damaging cytotoxic agents, including chemotherapy 
and radiotherapy, and targeted agents able to induce HR 
dysfunctions, such as CDK1, PI3K, PTEN and HSP90 
inhibitors or anti-angiogenic drugs. 
Ovarian cancer
Fong et al have has first demonstrated the activity of 
single agent PARP inhibitor olaparib in BRCA-deficient 
advanced ovarian, breast and prostate cancers [43], with 
grater activity observed in platinum sensitive ovarian 
cancer patients [44]. Response rates of 30% have been 
reported in a subsequent phase II studies conducted in 
refractory advanced BRCA-mutant ovarian cancer [45], 
suggesting BRCA1-2 mutations as potential predictive 
Table 1: Phase II and III clinical trials investigated PARP inhibitors in breast and ovarian cancer.
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biomarkers for clinical use. However another phase II 
study including both BRCA mutant and wild type patients 
with breast cancer and HGSOC showed encouraging 
activity also in the cohort of wild type, platinum-sensitive 
HGSOC patients [46], likely due to the acquired defects 
of HR genes responsible for “BRCA-like phenotype”, 
which conferred the same sensitivity to both platinum-
chemotherapy and PARP inhibition. All such findings 
have led to the design of a randomized phase III, placebo 
controlled trial, of olaparib as single agent maintenance 
therapy in patients with recurrent HGSOC who responded 
to prior platinum-based chemotherapy, showing a 
significant improvement of 3.6 months progression free 
survival (PFS) in the overall population (HR: 0.35, p < 
0·001), with the greatest increment of 6.9 months PFS (HR 
0.18, p < 0.0001) occurring in the subgroup of patients 
with BRCA mutations [47]. The updated analysis of the 
study 19 has recently shown a significant overall survival 
benefit limited to the BRCA mutant patients (34.9 vs 30.2 
months; HR: 0.62, p = 0.025), which was not extended to 
the wild type population (HR 0.83, p = 0.37). As expected 
adverse events like fatigue, anemia, nausea and vomiting 
were significantly higher with olaparib than placebo [48]. 
On the basis of such positive results olaparib was the first 
PARP-inhibitor receiving the approval by the European 
Medical Agency (EMA) at doses of 400 mg twice daily as 
maintenance therapy for platinum-sensitive patients with 
advanced HGSOC, fallopian tube, or primary peritoneal 
cancer, harboring BRCA-mutations. A companion 
diagnostic test has been also approved by FDA to identify 
mutations in BRCA1/2 genes using DNA obtained from 
a blood sample. Along with olaparib, several other PARP 
inhibitors, including veliparib, rucaparib and niraparib 
have shown encouraging activity and acceptable safety 
profile in early phase I-II studies. In particular the phase 
II randomized ARIAL 2 study of rucaparib has shown an 
objective response rate (ORR) of 80% and median PFS of 
12.8 months in BRCA-mutant platinum sensitive patients 
with recurrent ovarian cancer and ORR 39% with and 
median PFS of 7.2 months in BRCA wild type patients 
with a BRCA-like signature, compared to ORR of 13% 
and median PFS of 5 months in biomarker negative 
patients. Rucaparib was associated with a manageable 
safety profile, including nausea, asthenia/fatigue and 
ALT/AST elevations among the most common treatment-
related AEs [49, 50]. These impressive results led to 
the recent Breakthrough Therapy designation status of 
rucaparib by the FDA for the treatment of ovarian cancer, 
while the ARIEL3 randomized study is currently recruiting 
patients. Veliparib has recently shown a significant activity 
and tolerable safety profile as single agent in a phase II 
single arm trial including ovarian cancer patients carrying 
a germline BRCA1-2 mutation who progressed to prior 
chemotherapy regimens, reporting ORR of 35% and 20% 
in platinum-sensitive and platinum-resistant patients, 
respectively [51]. A phase 3 trial is currently ongoing in 
order to further elucidate the potential of this drug in such 
setting. Niraparib 300 mg/day has shown a good safety 
profile and a promising activity with ORR 40% in pre-
treated ovarian cancer patients with BRCA 1-2 mutations 
[52]. The phase III randomized ENGOT-OV16/NOVA 
trial investigated the PARP inhibitor niraparib as single 
agent maintenance therapy in patients with recurrent, 
platinum sensitive HGSOC, stratified by BRCA-mutation 
status. The study has met its primary end-point showing a 
significant PFS improvement both in BRCA-mutant (HR: 
0.27; p < 0.001) and in BRCA-wild type (HR: 0.45; p < 
0.0001) populations. A further analysis of BRCA-wild 
type patients identified the subgroup of HRD-positive 
patients who receive more benefit (HR: 0.38; p < 0.001) 
compared to HRD-negative patients (HR: 0.58; p < 
0.0226) [53]. The large benefit observed in the overall 
population included in the NOVA study could led to a 
fast approval of niraparib in the treatment of platinum 
sensitive recurrent ovarian cancer, regardless of BRCA-
status. An alternative approach has been investigated by 
another phase II randomized trial comparing olaparib plus 
chemotherapy (paclitaxel and carboplatin), followed by 
olaparib single agent maintenance versus chemotherapy 
alone in platinum-sensitive recurrent HGSOC patients. 
The results of such trial showed that combining olaparib 
200 mg twice daily for 10 days of each cycle with lower 
dose of carboplatin (AUC 4) plus paclitaxel, followed by 
olaparib 400 mg twice daily as maintenance treatment is 
an effective and tolerable option leading to a significant 
2.6-month PFS advantage (HR 0.51, p = 0.0012), with 
the greatest clinical benefit in BRCA-mutated patients 
(HR: 0.21, p = 0.0015) [54]. The addition of veliparib to 
cyclophosphamide didn’t improve RR and PFS in patients 
with recurrent HGSOC [55], while another phase II 
randomized study comparing veliparib plus temozolomide 
vs PLD in the same setting of patients has just completed 
recruitment (NCT01113957, https://clinicaltrials.gov/ 
). A very promising strategy emerged from the phase II 
randomized trial by Liu et al. which showed a further PFS 
benefit from adding the anti-angiogenic agent cediranib 
to olaparib for platinum-sensitive, recurrent, HGSOC, 
fallopian tube, or primary peritoneal cancer (median PFS 
17.7 vs 9 months; (HR: 0.42; p = 0·005) [56], warranting 
investigation in a phase III ongoing trial. Similarly a 
phase I-II study is currently comparing tolerability and 
efficacy of niraparib alone versus niraparib-bevacizumab 
combination versus sequential bevacizumab and niraparib 
in platinum sensitive relapsed ovarian cancer [57], while 
the PAOLA1 trial is currently investigating first-line 
chemotherapy with bevacizumab plus olaparib or placebo 
as maintenance treatment. Finally the combination of 
olaparib and PD-L1 checkpoint inhibitor Durvalumab 
has shown promising durable long-term responses and a 
tolerable safety profile in pre-treated ovarian cancer and 
triple negative breast cancer (TNBC) patients [58].
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Breast cancer
As for ovarian cancer, first proof-of-concept trials 
have shown a significant activity of PARP inhibitors 
in women with advanced breast cancer and BRCA1-2 
mutations [43], reporting ORR to olaparib nearly to 40% 
and median PFS 5.7 months in the overall population 
and ORR of 54% in TNBC patients [59]. Simultaneously 
another phase II study including both BRCA mutant 
and wild type patients with breast cancer and HGSOC 
showed no confirmed clinical responses in breast cancer 
patients according to RECIST criteria but only a partial 
reduction in tumor size for 5 (50%) of patients with BRCA 
mutations [46]. Recently the results of a multicenter phase 
II study confirmed that encouraging responses to olaparib 
were observed across different tumor types associated with 
germline BRCA1/2 mutations including breast, ovarian, 
prostate, and pancreatic cancer who received prior 
chemotherapies, and AEs most frequently reported were 
fatigue, nausea, and vomiting [60]. All these evidences 
have led to the design of phase III Olympia trials which 
are currently investigating the activity of olaparib as 
single agent both in metastatic and adjuvant treatment 
of breast cancer patients with germ-line BRCA1-2 
mutations. Rucaparib has shown preliminary activity 
in a phase II study including patients with BRCA1-2-
mutated metastatic breast cancer [61], and it will be 
early under evaluation in advanced breast cancer patients 
with a BRCA-like profile, including a specific genomic 
signature or somatic BRCA mutations (NCT02505048, 
https://clinicaltrials.gov/). However the addition of 
rucaparib to cisplatin failed to improve the DFS in patients 
with TNBC who had residual disease after preoperative 
chemotherapy [61]. Recently early phase I-II studies 
investigated both tolerability and activity of veliparib 
in combination with different chemotherapy regimens, 
including temozolomide, carboplatin, irinotecan, 
cisplatin, vinorelbine and cyclophosphamide in pre-
treated advanced breast cancer patients with or without 
BRCA mutations, showing RR between 20% and 40%. 
Veliparib is currently under investigation in two phase III 
randomized trials comparing veliparib plus carboplatin-
based regimens both in advanced and neoadjuvant setting, 
including BRCA-mutated and TNBC, respectively 
(NCT02163694; NCT02032277, https://clinicaltrials.gov/ 
). Niraparib 300 mg/day has shown a good safety profile 
and a promising activity with ORR of 50% in pre-treated 
breast cancer patients with BRCA1-2 mutations [52], and 
is currently under investigation as single agent in the phase 
III randomized BRAVO trial in this setting of patients. 
Finally talazoparib is a PARP inhibitor currently under 
investigation as single agent in BRCA mutated breast 
cancer both in a phase III study in metastatic disease 
and in a pilot phase II study as neoadjuvant treatment 
(NCT02282345, https://clinicaltrials.gov/ ).
Other malignancies
According to the first evidences reported by Fong et 
al, the results of a multicenter phase II study by Kaufman 
et al, have recently showed encouraging responses to 
olaparib across different tumor types associated with 
germline BRCA1/2 mutations including breast, ovarian, 
prostate, and pancreatic cancer who received prior 
chemotherapy regimens [60], confirming that BRCA1/2 
germline status defines a target population responsive to 
PARP inhibition, regardless of tumor anatomic origin and 
histotype. Currently phase II-III studies are investigating 
the potential activity of PARP inhibitors in genetically 
defined advanced solid tumors harboring BRCA1/2 
mutations. Particularly the phase III randomized POLO 
study is evaluating single agent olaparib as ‘switch 
maintenance’ therapy in patients with BRCA1/2 mutated 
advanced pancreatic cancer who have not progressed 
on first-line platinum chemotherapy (NCT02184195, 
https://clinicaltrials.gov/). However, except for ovarian 
and breast cancers, BRCA1/2 germline mutations are 
less frequently observed in other malignancies, including 
gastric and pancreatic cancers (5%-10%), melanoma (5%) 
[62], prostate and NSCLC (1%-2%) [63, 64]. Beyond 
BRCA1/2, anti-tumor activity of PARP inhibitors was also 
reported in sporadic (BRCA1/2 wild type) cancers with 
BRCA-like phenotype. Recently a phase II study by Mateo 
et al. has shown promising antitumor activity of olaparib 
in patients with sporadic advanced CRPC who progressed 
to prior anticancer treatments and who had DNA-repair 
genes defects identified by NGS, accounting for about 25-
30% of all sporadic CRPC patients [65]. Another phase 
II study is currently evaluating olaparib plus abiraterone 
in advanced sporadic CRPC including the assessment of 
activity in ETS fusion-positive tumors, which represent 
about 50% of all CRPC patients, in order to demonstrate 
its predictive role for clinical setting (NCT01972217, 
https://clinicaltrials.gov/). Similarly clinical studies are 
investigating the activity of PARP inhibitors in Ewing’s 
sarcoma with either EWS-FLI1 or EWS-ERG genomic 
fusions. Since pre-clinical studies demonstrated the 
potential role of PARP inhibitors as chemo/radio-
sensitizers several conducted/ongoing studies investigated 
the addition of such agents to chemotherapy regimens in 
different sporadic tumor types. Interesting activity has 
been recently observed with veliparib plus chemotherapy 
combinations both in melanoma patients with unknown 
BRCA/HR status [66, 67], and in untreated NSCLC 
patients with squamous histology, reaching an hazard ratio 
of 0.50 for PFS, and 0.71 for OS [68], and leading to a 
randomized phase III ongoing study in this subgroup of 
patients (NCT02264990, https://clinicaltrials.gov/ ), while 
the addition of iniparib to first-line platinum-gemcitabine 
did not improve ORR in advanced NSCLC patients [69]. 
The addition of olaparib to paclitaxel as second-line 
therapy in patients with recurrent/metastatic gastric cancer 
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was well tolerated and showed a statistically significant 
improvement in OS in the overall included population, 
with a larger benefit in the subgroup of patients with low 
ATM expression [70], and is currently under investigation 
in a phase III randomized study (NCT01924533, 
https://clinicaltrials.gov/). Randomized phase II and III 
studies are ongoing to evaluate the efficacy of veliparib 
plus chemotherapy regimens as first-line treatment in 
advanced colorectal cancer (NCT02305758, https://
clinicaltrials.gov/) and glioblastoma (NCT02106546, 
https://clinicaltrials.gov/), respectively, while a phase II 
randomized study is comparing olaparib plus gefitinib vs 
gefitinib alone in advanced NSCLC patients with EGFR 
activating mutations. Finally several studies are also 
exploring the role of PARP inhibitors in combination with 
radiotherapy in different tumor types, including NSCLC, 
head and neck cancer, esophageal cancer, and pancreatic 
cancer. Recently a meta-analysis including randomized 
controlled trials (RCTs) of PARP inhibitors in cancer has 
shown that such agents significantly improve the PFS of 
overall included population, and that such benefit was 
even greater in the subgroup of patients harboring BRCA 
1/2 mutations, but failed to improve OS of cancer patients 
[12], and this need to be taken into account to optimize the 
design of further clinical studies.
KNOWN MECHANISMS OF PRIMARY 
RESISTANCE
It has been already demonstrated that the activity 
of PARP inhibitors depends from the different levels of 
HR deficiency [71]. Studies in vitro and in vivo allowed 
to identify different genes involved in the HR pathway, 
whose alterations are responsible for different levels of 
HR deficiency finally influencing the sensitivity to PARP 
inhibition [72-75]. 
Certainly a well known mechanism of primary 
resistance to PARP inhibitors is represented by the 
mutation status of BRCA-1 and BRCA-2 genes.  Indeed 
it has been shown that breast cancer cells with BRCA1/2 
dysfunctions have a greater sensitivity to the PARP 
inhibitors because of the simultaneous ineffectiveness 
of both BER and HR mechanisms, respectively linked to 
the single (PARP inhibitors) and double (loss of function 
of BRCA1 and/or BRCA2) strand DNA damage,  finally 
producing a chromosomal instability, cell cycle arrest and 
apoptosis [35, 71].
Another important gene involved in the HR pathway 
is PTEN. PTEN encodes a phosphatase protein regulating 
also the PI3K signaling pathway. Mutations and loss of 
PTEN function have been widely correlated with human 
carcinogenesis [76]. In glioblastoma cells, the deficiency 
of PTEN is of crucial importance since it contributes 
to an increased sensitivity to a temozolamide derivate 
(N-methylN’-nitro-N-nitrosoguanidine - MNNG). Indeed 
double strand DNA damages can’t be repaired because 
of the deficiency PTEN function, therefore resulting in 
cells death by apoptosis [77, 78]. The same mechanism 
is responsible for an increased activity of PARP inhibitors 
also in endometrial or prostate cancer cells with loss of 
PTEN function compared to wild-type cells, suggesting a 
potential role of PTEN as a marker of primary resistance 
to PARP inhibitors [79, 80]. 
PI3K is another important protein involved in 
the resistance mechanisms, also because of its close 
relationship with the above mentioned PTEN signaling 
pathway. PI3K is a member of a family of lipid kinases, 
and its activation is required for the functionality of HR 
pathway [81]. Recent studies have shown that an increased 
BRCA gene down-regulation, caused by PI3K protein 
target inhibition, makes triple-negative breast cancer 
cells more sensitive to PARP inhibitors, suggesting as 
PI3K functioning could represent a possible mechanism 
involved in the occurrence of primary resistance [82, 83]. 
The discovery of the correlation between DNA damage 
and PI3K activity has also led to the investigation of 
different PARP inhibitors in solid tumors characterized 
by PI3K gene alterations, such as NSCLC and colorectal, 
whereas its prognostic and/or predictive role is currently 
under investigation [84, 85]. 
The ATM gene also seems to have a role in the 
HR mechanisms, therefore on the sensitivity/resistance 
to PARP inhibitors. The protein kinase ATM shares the 
chemical group -COOH with PI3K protein and it is 
particularly involved in the repair of double strand DNA 
damage caused by ionizing radiation. The dysfunction of 
such protein leads to an accumulation of DNA damage 
by oxidative stress. Previous studies have shown that the 
functionality of ATM and PARP are absolutely necessary 
for embryonic development of mice, while a functional 
deficiency of both proteins led to their death within the first 
few days of life[86]. Subsequently, other studies clarified 
that PARP1 is more active  in cancer cells that, due to the 
lack of function of ATM, accumulated DNA damage (most 
represented and studied in prostate cancer, breast cancer, 
mantle cell lymphoma) [65, 87, 88]. Being PARP-1 and 
ATM both involved in DNA repair mechanisms (BER and 
HR respectively), the synergic action between these two 
proteins could explain the PARP inhibitors resistance of 
cancer cells leading wild type ATM [86, 89]. 
As we know NHEJ is defective in about 40% of 
ovarian cancers, and a recent preclinical study has shown 
that it is associated with resistance to PARP inhibitors in 
ex vivo primary cultures independently from HR function 
[90] (Figure 1).
Although the validation of the above mentioned 
primary resistance  processes is still under investigation, 
because of the recent advent of PARP inhibitors, it is 
clear how an important goal in the near future should be 
represented by the identification of predictive markers of 
response and /or resistance to PARP inhibitors to better 
select ideal patients to treat with these drugs. In this sense, 
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a potential role could be played by miRNAs, fractions of 
non-coding RNA that regulate the post-trascriptional gene 
expression [91]. 
Indeed there are several data that suggest that 
miRNAs take part in modulating the cancer cells’ response 
to PARP inhibitors. Among the most common miRNAs 
identified in both ovarian cancer and triple-negative breast 
cancer, mir-9, mir-506, mir-96, mir-182 and mir-206 are 
worthy of mention.  Liquid biopsy could represent an ideal 
tool to study this interesting but at the same time greatly 
complex and confounding scenario [92-96]. 
NEW FINDINGS ON ACQUIRED 
RESISTANCE
Since the advent of PARP inhibitors for cancer 
treatment, there are growing evidences showing that not 
all patients with BRCAness genes alterations report the 
same treatment responses. Commonly to other targeted 
treatments the majority of tumors will develop acquired 
resistance within 1 year of therapy, leading to the disease 
progression and the subsequent discontinuation of cancer 
treatment [73]. It’s likely that the different emerging 
mechanisms of resistance may depend from the original 
BRCAness gene alterated, ultimately leading to different 
patterns of treatment response observed in clinical setting 
[97].
Considering the recent introduction of PARP 
inhibitors for clinical use, there is currently very 
limited understanding about the molecular mechanisms 
underlying the occurrence of acquired resistance to this 
family of drugs. The majority of available data have 
emerged from pre-clinical studies, showing several 
alterations responsible for the partial or complete 
restoration of the HR repair function, including: secondary 
mutations in BRCA1/2, Pgp overexpression, and the loss 
of 53BP1 protein function. Several studies have shown 
the occurrence of secondary mutations in the alterated 
BRCA1-2 genes during PARP inhibitors therapy, leading 
to a partial restoration of both BRCA protein and the 
related HR repair function, with the subsequent induction 
of resistance [97-99]. Mutations of C-terminal domain of 
BRCA1 (BRCT) may promote PARP inhibitor resistance 
preventing the recruitment of protein complexes which 
are useful in the site of the damaged DNA [100]. The 
same mechanism has been shown in human tumor cell 
lines harboring BRCA2 6174delT frameshift mutation. 
The result of such alteration is a truncated, non functional 
protein, because of the loss of C-terminal portion, BRC 
repeats, DNA-binding/DSS1 interaction domain, finally 
resulting in both platinum and PARP-inhibitors resistant 
phenotype [97].The over-expression of Glicoprotein-P 
(Pgp) as mechanism of resistance has been first observed 
in ovarian cell-lines receiving combination chemotherapy 
treatment with  Paclitaxel plus Doxorubicin. Recently 
a significant up-regulation of Pgp associated mdr1 a/b 
genes has been identified in ovarian cell lines undergone 
prolonged treatment with olaparib. In-vivo studies in 
mouse models have clearly shown as such drug may be 
immediately ejected by tumor cells by overexpression of 
Pgp on the cell surface, confirming  a potential role of 
such protein in the development of acquired resistance to 
Olaparib [101]. However such kind of resistance could be 
overcome by the addition of Pgp inhibitors to olaparib, as 
well as using other members of PARP inhibitors family 
which are less sensitive to Pgp mechanism of action, such 
as veliparib.
In 2010, in vitro and in vivo-studies by Bouwman 
and Bounting, respectively, have first demonstrated that 
loss of P53-binding protein 1 (53BP1) function was 
associated with the partial restoration of the HR repair 
function in BRCA1 mutated models [102, 103]. Indeed 
53BP1 protein is involved in the control of DNA clivage at 
DSBs mediating BRCA-mutated cells death during PARP-
inhibitors treatment. Recent evidences have shown also 
decreased levels of 53BP1 in patients with ovarian cancer 
who developed acquired resistance to both platinum-
based chemotherapy and PARP-inhibitors, confirming 
a potential role of such protein in the occurrence of 
resistance. Other data emerging from in vivo-studies have 
shown the simultaneous occurrence of different alterations 
responsible for the development of resistance to PARP 
inhibition in mouse models, including BRCA1 secondary 
mutations, Pgp over-expression and loss of 53BP1 protein 
function [102].
CONCLUSIONS
BRCA mutations increased tumor-cells sensitivity 
to PARP inhibitors by synthetic lethality and several 
compounds targeting the PARP enzymes system have 
been evaluated in clinical trials. In this review we have 
summarized the most relevant clinical trials carried out 
in patients affected by advanced breast or ovarian cancer 
or other malignancies and treated with PARP inhibitors 
alone or in combination with chemotherapy. The positive 
results of such studies have recently led to the approval 
of the first PARPi olaparib as maintenance therapy for 
platinum-sensitive patients with advanced, recurrent 
HGSOC, fallopian tube, or primary peritoneal cancer, 
harboring BRCA-mutations. Therefore offering to test for 
germline BRCA1/2 mutations should now be considered 
a routine part of clinical practice, in order to provide the 
best treatment strategy to each patient. Even if BRCA1/2 
mutations have shown to be highly predictive of PARPi 
activity in the majority of studies, PARPi have shown also 
activity in patients without BRCA-mutations, especially 
in HRD-positive population. Testing for somatic BRCA 
mutations and HRD-signature is currently a developing 
area with interesting implications for clinical practice. 
There are some mechanisms that have been reported as 
responsible of primary resistance to these molecules. 
Oncotarget23900www.impactjournals.com/oncotarget
BRCA wild type status, PTEN, PI3K and ATM have 
been evaluated as markers of primary resistance. Many 
studies aim to identify positive predictive markers to select 
patients who may benefit most from PARP inhibition. In 
particular it has been hypothesized that the different action 
of PARP inhibitors may depend on the expression of 
some miRNAs. All patients initially responding to PARP 
inhibition at some time later develop acquired resistance. 
The suggested mechanisms of acquired resistance include 
secondary mutations in BRCA1-2, Pgp over-expression 
and loss of 53BP1 protein function. Further pre-clinical 
and clinical studies are required to better define the role 
of these innovative targeted agents in cancer treatment. 
It seems reasonable that for the peculiar mechanisms of 
action, PARP inhibitors could be usefully combined with 
both DNA damaging cytotoxic agents, radiotherapy, and 
with other targeted therapies. Initial results of combining 
PARPi with anti-angiogenic drugs are promising, 
leading to several randomized studies in different lines 
of treatment. Finally PARPi and PD1/PDL1 checkpoint 
inhibitors combinations have recently shown durable 
responses, emerging as another promising strategy to 
expand the treatment arsenal against cancer.
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